Glucovance is a brand-name combination medication that contains the active ingredients metformin and glyburide. It belongs to the therapeutic class of diabetes management and is formulated as a pill. In Hong Kong, Glucovance is a prescription-only product, regulated by the Department of Health. The tablets are available in two strengths: 400 mg/2.5 mg and 500 mg/5 mg (metformin / glyburide). Metformin is a big-biguanide that reduces glucose production by the liver, while glyburide is a sulfonylurea that stimulates insulin release from pancreatic β-cells. Together they address both insulin resistance and insufficient insulin secretion, two key defects in type 2 diabetes.
Metformin component
Decreases hepatic gluconeogenesis, leading to lower fasting blood glucose.
Improves peripheral insulin sensitivity, enhancing glucose uptake in muscle and fat.
Does not cause hypoglycemia when used alone because it does not increase insulin secretion.
Glyburide component
Binds to sulfonylurea receptors on pancreatic β-cells, closing potassium channels.
This depolarizes the cell membrane, causing calcium influx and insulin release.
The insulin surge helps lower post-prandial glucose but carries a risk of hypoglycemia, especially in the elderly or those with irregular meals.
Combined effect
Metformin addresses baseline hyperglycemia, while glyburide tackles spikes after meals.
The combination often achieves better glycemic control than either agent alone, allowing lower individual doses and potentially reducing side-effects associated with high-dose monotherapy.
Typical patients are adults with a documented diagnosis of type 2 diabetes who require additional glucose-lowering therapy beyond lifestyle measures and single-agent drugs.
Major interactions
Cimetidine, trimethoprim-sulfamethoxazole: May increase metformin plasma levels, raising lactic acidosis risk.
Azole antifungals (e.g., ketoconazole): Inhibit CYP2C9, potentially increasing glyburide concentrations and hypoglycemia risk.
Moderate interactions
Beta-blockers: May mask hypoglycemia symptoms.
Thiazide diuretics: Can impair glucose tolerance, counteracting therapeutic effect.
General advice
Inform healthcare providers of all prescription, over-the-counter, herbal, and supplement use before starting Glucovance.
Standard dosing (based on available tablet strengths)
Initial dose: 400 mg/2.5 mg tablet taken twice daily with meals.
Titration: After 1-2 weeks, the dose may be increased to 500 mg/5 mg twice daily, depending on glycemic response and tolerability.
Maximum dose: Typically not to exceed 500 mg/5 mg twice daily without specialist review.
Special populations
Renal impairment: Reduce to 400 mg/2.5 mg once daily; avoid if eGFR < 30 mL/min/1.73 m².
Elderly: Start at 400 mg/2.5 mg once daily; increase only if glucose targets are not met and hypoglycemia has not occurred.
Administration guidance
Swallow tablets whole; do not crush or chew.
Take with the first bite of each main meal to enhance absorption and reduce stomach upset.
Store at room temperature, away from moisture and direct sunlight.
Missed dose
Take the missed tablet as soon as you remember if it is still within a reasonable time before the next scheduled dose.
Do not double the dose to compensate for a missed tablet.
Overdose
Symptoms may include severe nausea, vomiting, abdominal pain, and signs of hypoglycemia (e.g., confusion, sweating).
Seek emergency medical attention; treatment may involve activated charcoal, intravenous glucose, and supportive care.
Discontinuation
Gradual tapering is not required for metformin; however, abrupt cessation of glyburide can precipitate hyperglycemia.
If stopping therapy, monitor blood glucose closely and discuss alternative regimens with your provider.
Baseline labs before initiation
Fasting plasma glucose, HbA1c, serum creatinine/eGFR, liver function tests.
Ongoing monitoring
HbA1c every 3 months until stable, then at least biannually.
Serum creatinine/eGFR at least annually, more frequently if renal function is borderline.
Periodic assessment for symptoms of hypoglycemia or lactic acidosis.
When to contact a healthcare professional
Persistent gastrointestinal distress beyond the first few weeks.
Recurrent hypoglycemic episodes.
Unexplained shortness of breath, muscle pain, or fatigue (possible lactic acidosis).
This article provides educational information about Glucovance and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Glucovance can be prescribed to patients with stable cardiovascular disease, but clinicians will evaluate individual risk, particularly the potential for hypoglycemia, which can trigger cardiac events. Ongoing monitoring and dose adjustments may be necessary.
Alcohol can increase the risk of lactic acidosis associated with metformin and may potentiate hypoglycemia from glyburide. Limit intake and discuss any alcohol consumption with your healthcare provider.
Persistent gastrointestinal upset is a common metformin side effect. Try taking the medication with food, and consider a dose reduction after consulting your provider. If symptoms continue, an alternative regimen may be recommended.
Carry the medication in its original labeled container, keep it in your carry-on luggage, and have a copy of the prescription. Ensure you know the local regulations regarding import of prescription drugs into the destination country.
Non-steroidal anti-inflammatory drugs (NSAIDs) can affect renal function, potentially increasing metformin levels and the risk of lactic acidosis. Use NSAIDs sparingly and discuss pain-relief options with your clinician.
Switching is possible and often simplifies dosing. Your provider will calculate an equivalent dose and may adjust the regimen based on your current glycemic control and tolerance.
Both contain metformin and a sulfonylurea, but Glucovance pairs metformin with glyburide, whereas Janumet pairs metformin with sitagliptin (a DPP-4 inhibitor). The mechanisms and side-effect profiles differ, influencing the choice of therapy.
Coverage varies by individual insurance plans and the Hospital Authority’s formulary. Check with your insurer or the Hospital Authority for eligibility and reimbursement details.
Metformin begins lowering fasting glucose within a few days, while glyburide’s effect on post-prandial glucose can be seen shortly after dosing. Full therapeutic effect typically stabilizes after 4-6 weeks of consistent use.
